Box (NYSE: BOX) 8.7% HIGHER; reported Q1 EPS of ($0.28), $0.03 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $65.6 million versus the consensus estimate of $63.7 million. Q2 revenue is expected to be in the range of $69 to $70 million, versus the consensus of $67 million. FY16 revenue is expected to be in the range of $286 to $290 million, compared to previous guidance of $281 to $285 million and the consensus of $283 million.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) 5.5% LOWER; Alnylam Pharma (NASDAQ: ALNY) announced that it has